VYNE THERAPEUTICS INC (VYNE)
US92941V3087 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 19.07M | 30.62M | 30.90M | 42.30M | 57.60M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | 0.00 | |||
| Receivables | N/A | 0.00 | 5.20M | 7.60M | 15.80M | |||
| Inventories | N/A | N/A | N/A | 7.30M | 7.40M | |||
| Other Current Assets | 71.16M | 65.34M | 2.20M | 6.00M | 6.50M | |||
| Total Current Assets | 90.22M | 95.96M | 38.30M | 63.20M | 87.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 180.00K | 207.00K | 0.00 | 400.00K | 2.10M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.27M | 1.51M | 2.50M | 3.50M | 4.30M | |||
| Total Non-Current Assets | 1.45M | 1.72M | 2.50M | 3.80M | 6.40M | |||
| TOTAL ASSETS | 91.68M | 97.69M | 40.80M | 67.00M | 93.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 3.76M | 4.23M | 4.40M | 8.90M | 12.20M | |||
| Accounts Payable | 2.79M | 1.66M | 2.40M | 6.50M | 4.80M | |||
| Other Current Liabilities | 376.00K | 1.65M | 2.60M | 3.00M | 4.80M | |||
| Total Current Liabilities | 6.93M | 7.54M | 9.30M | 18.40M | 21.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 33.20M | |||
| Other Non-Current Liabilities | 1.38M | 1.41M | N/A | 0.00 | 1.30M | |||
| Total Non-Current Liabilities | 1.38M | 1.41M | 0.00 | 0.00 | 34.40M | |||
| TOTAL LIABILITIES | 8.31M | 8.95M | 9.30M | 18.40M | 56.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -697.59M | -691.34M | -662.70M | -639.50M | -566.20M | |||
| Additional Paid In Capital | 781.02M | 780.04M | 693.90M | 688.20M | 603.70M | |||
| Minority Interest | N/A | 0.00 | N/A | N/A | N/A | |||
| Common Shares | 1.00K | 1.00K | 200.00K | 0.00 | 0.00 | |||
| Shares Outstanding | 14.30M | 14.10M | 3.20M | 3.00M | 2.40M | |||
| Tangible Book Value per Share | 5.83 | 6.29 | 9.75 | 16.20 | 15.63 | |||
| Total Shareholders' Equity | 83.37M | 88.73M | 31.40M | 48.60M | 37.50M | |||
| TOTAL LIABILITIES AND EQUITY | 91.68M | 97.69M | 40.80M | 67.00M | 93.70M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.89 | |||
| Current Ratio | 13.02 | 12.73 | 4.12 | 3.43 | 4.00 | |||
| Return On Assets (ROA) | -31.72% | -29.13% | -56.89% | -109.45% | -272.75% | |||
| Return On Equity (ROE) | -34.88% | -32.06% | -73.92% | -150.88% | -681.52% | |||
All data in USD